Precision BioSciences' PBGENE-HBV Shows Durable RNA Loss in Hepatitis B Trial

  • Precision BioSciences selected for late-breaking oral presentation at AASLD The Liver Meeting 2026 on November 8.
  • PBGENE-HBV trial shows durable pgRNA loss in both HBeAg positive and negative patients.
  • ELIMINATE-B Phase 1 trial enrolling globally with goal of defining optimal dose for cccDNA elimination.
  • FDA has granted Fast Track designation to PBGENE-HBV.

Precision BioSciences' presentation at AASLD highlights the potential of its ARCUS platform in achieving a functional cure for chronic hepatitis B, a condition with significant unmet medical need. The durable pgRNA loss data positions PBGENE-HBV as a leading candidate in the gene editing space, with implications for both Precision's market valuation and the broader adoption of in vivo gene editing therapies. The global enrollment in the ELIMINATE-B trial underscores the clinical and commercial significance of this development.

Clinical Efficacy
Whether durable pgRNA loss translates to sustained viral cure in chronic hepatitis B patients.
Regulatory Pathway
The pace at which FDA Fast Track designation accelerates PBGENE-HBV's approval process.
Market Positioning
How Precision BioSciences differentiates ARCUS platform in the competitive gene editing space.